Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication

被引:32
|
作者
Zhang, Ya-Wen [1 ,2 ]
Hu, Wei-Ling [1 ,2 ]
Cai, Yuan [1 ]
Zheng, Wen-Fang [1 ,2 ]
Du, Qin [3 ]
Kim, John J. [4 ]
Kao, John Y. [5 ]
Dai, Ning [1 ]
Si, Jian-Min [1 ,2 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gastroenterol, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China
[2] Zhejiang Univ, Inst Gastroenterol, Hangzhou 310016, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Gastroenterol, Hangzhou 310009, Zhejiang, Peoples R China
[4] Loma Linda Univ, Div Gastroenterol, Loma Linda, CA 92354 USA
[5] Univ Michigan, Dept Internal Med, Div Gastroenterol, Michigan Med, Ann Arbor, MI 48109 USA
关键词
Helicobacter pylori; Furazolidone; Quadruple regimen; Side effects; Eradication; TRIPLE THERAPY; BISMUTH; RESISTANCE; REGIMENS; GASTROENTEROLOGY; CLARITHROMYCIN; METAANALYSIS; RABEPRAZOLE; 1ST-LINE; EFFICACY;
D O I
10.3748/wjg.v24.i40.4596
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To evaluate the outcomes of furazolidone- and amoxicillin-based quadruple therapy for treatment of Helicobacter pylori (H. pylori) infection and identify predictors of failed eradication. METHODS Patients with H. pylori infection treated with furazolidone, amoxicillin, bismuth, and proton pump inhibitor therapy (January 2015 to December 2015) who received the C-13-urea breath test > 4 wk after treatment were evaluated. Demographic and clinical data including prior H. pylori treatment attempts, medication adherence, alcohol and cigarette consumption during therapy, and treatment-related adverse events were recorded by reviewing medical records and telephone surveys. H. pylori eradication rates for overall and subgroups were evaluated. Multivariate analysis was performed to identify independent predictors of failed H. pylori eradication. RESULTS Of the 992 patients treated and retested for H. pylori infection, the overall eradication rate was 94.5% [95% confidence interval (CI): 94.1%-95.9%]. H. pylori eradication rate of primary therapy was 95.0% (95%CI: 93.5%-96.5%), while that of rescue therapy was 91.3% (95%CI: 86.8%-95.8%). Among the 859 patients who completed the study protocol, 144 (17%) reported treatment-related adverse events including 24 (3%) leading to premature discontinuation. On multivariate analysis, poor medication adherence [adjusted odds ratio (AOR) = 6.7, 95%CI: 2.8-15.8], two or more previous H. pylori treatments (AOR = 7.4, 95%CI: 2.2-24.9), alcohol consumption during therapy (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking during therapy (AOR = 1.9, 95%CI: 0.9-4.3) were associated with failed H. pylori eradication. CONCLUSION Furazolidone- and amoxicillin-based quadruple therapy for H. pylori infection in an area with a high prevalence of clarithromycin resistance demonstrated high eradication rates as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence from alcohol during therapy and strict medication adherence may further optimize H. pylori eradication.
引用
收藏
页码:4596 / 4605
页数:10
相关论文
共 50 条
  • [41] High Dose Amoxicillin-Based First Line Regimen is Equivalent to Sequential Therapy in the Eradication of H. pylori Infection
    Franceschi, Francesco
    Campanale, Mariachiara
    Finizio, Rosalba
    Barbaro, Federico
    Tortora, Annalisa
    Gigante, Giovanni
    Cesario, Valentina
    Calcinaro, Sara
    Marsiliani, Davide
    Carroccia, Annarita
    Silveri, Niccolo Gentiloni
    Curro, Diego
    Cammarota, Giovanni
    Gasbarrini, Giovanni
    Gasbarrini, Antomo
    GASTROENTEROLOGY, 2011, 140 (05) : S149 - S149
  • [42] Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease
    Ghadir, M. R.
    Shafaghi, A.
    Iranikhah, A.
    Pakdin, A.
    Joukar, F.
    Mansour-Ghanaei, F.
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2011, 22 (01): : 1 - 5
  • [43] Clostridium difficile infection associated with bismuth-based quadruple therapy (Pylere®) for Helicobacter pylori eradication
    Castro-Fernandez, Manuel
    Marques-Ruiz, Alberto
    Camara-Baena, Sergio
    Grande-Santamaria, Lourdes
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2019, 42 (07): : 459 - 460
  • [44] Modified Amoxicillin Triple Therapy vs Standard Triple Therapy for Eradication of Helicobacter Pylori Infection
    Sollano, Jose D., Jr.
    Romano, R. P.
    Dalupang, C. D.
    Chan, M. M.
    Tablante, M. C.
    De Lunas, K. C.
    Fernandez, D. F.
    Lo, V. S., Jr.
    DIGESTION, 2021, 102 (01) : 105 - 105
  • [45] Success Rate of Furazolidone-Based Triple Therapy for Eradication of Helicobacter Pylori in Children
    Najafi, Mehri
    Khodadad, Ahmad
    Fallahi, Gholamhossein
    Farahmand, Fatemeh
    Motamed, Farzaneh
    Sobhani, Mohammad
    IRANIAN JOURNAL OF PEDIATRICS, 2009, 19 (03) : 244 - 248
  • [46] Triple therapy with lansoprazole, clarithromycin, and amoxicillin is highly effective in the eradication of Helicobacter pylori infection
    Fennerty, B
    Bianchi, T
    Rose, P
    Pilmer, B
    Kidd, S
    Siepman, N
    GASTROENTEROLOGY, 1997, 112 (04) : A116 - A116
  • [47] Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy
    Chen, Qi
    Zhang, Wei
    Fu, Qingyan
    Liang, Xiao
    Liu, Wenzhong
    Xiao, Shudong
    Lu, Hong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (12): : 1736 - 1742
  • [48] Quadruple therapy for Helicobacter pylori infection reply
    Liou, Jyh-Ming
    Lee, Yi-Chia
    Wu, Ming-Shiang
    LANCET, 2013, 381 (9876): : 1459 - 1460
  • [49] Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori
    Wang, Junxian
    Cao, Yuping
    He, Wei
    Li, Xiaoping
    MEDICINE, 2021, 100 (51) : E28323
  • [50] Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication
    Korman, MG
    Bolin, TD
    Engelman, JL
    Pianko, S
    HELICOBACTER, 1997, 2 (03) : 140 - 143